Bausch Health Announces US$50 Million Share Repurchase Program
The program is intended to manage potential dilution from future employee equity-based compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bausch Health (BHC) has authorized a share repurchase program allowing purchases of common shares for up to US$50 million.
The company says the primary objective is to manage potential dilution from future employee equity-based compensation. Purchases may begin November 3, 2026, and the program will end no later than November 3, 2027. Repurchases cannot exceed 5% of the 374,266,716 common shares outstanding as of October 23, 2026. Shares acquired will be cancelled. Purchases may occur in U.S. open markets at prevailing prices, subject to a maximum price set by the board; actual purchases depend on market conditions, legal requirements and other factors.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Up to US$50 million authorized for common-share repurchases beginning as early as November 3, 2026. 2.1% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.All repurchased shares will be cancelled, removing acquired shares from the outstanding share count.
Negative
- None.
Details
Market move: BHC +12.95% vs previous close. share repurchase program
On Oct 28, the day this news came out, the latest delayed price for BHC is 12.95% above the previous close. Argus tracked a peak move of +5.8% during the session. Our momentum scanner has recorded 82 alerts for this stock so far that day. The latest delayed price is $7.82. Relative volume is very high at 4.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Maximum aggregate repurchase price
- US$50 million
- Authorized share repurchase program
- Program start
- November 3, 2026
- Purchases may commence
- Program end
- November 3, 2027
- Program terminates no later than this date
- Repurchase limit
- 5%
- Maximum share repurchases, based on 374,266,716 common shares outstanding as of October 23, 2026
AI-generated analysis. How Rhea-AI works. Not financial advice.
The primary objective of the Share Repurchase Program is to manage the potential dilutive impact of future employee equity-based compensation.
Purchases under the Share Repurchase Program may commence on November 3, 2026, and the Share Repurchase Program will terminate no later than November 3, 2027. Purchases may be made in the open market on the New York Stock Exchange and other published markets in
Common Shares will be purchased at the prevailing market price at the time of purchase, subject to a maximum price established by the Board of Directors. The value of any purchases in Canadian dollars will depend on the market price and the applicable exchange rate at the time of each purchase.
The actual number of Common Shares repurchased, and the timing and price of any repurchases, will depend on market conditions, applicable legal requirements and other factors. The Company will not repurchase more than
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
|
Investor Contact: |
Media Contact: |
|
Garen Sarafian |
Alexis Navratil |
|
(877) 281-6642 (toll free) |
(848) 264-0934 |
|
|
|
|
BHC- FINANCIAL |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-us50-million-share-repurchase-program-302922572.html
SOURCE Bausch Health Companies Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.